Acepromazine Maleate Tablets

Manufacturer
ZYVET ANIMAL HEALTH INC.
Effective date
2026-09-11
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
2
Source
daily-update
Hydrated at
2026-10-13 04:01:59

Label at a glance#

ProductAcepromazine maleate
Active ingredientACEPROMAZINE MALEATE
Label structure18 sections

Storage and handling

Storage: Store at 20° - 25°C (68° - 77°F). Excursions permitted to 40°C (104°F).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For use in dogs only.

SPL UNCLASSIFIED SECTION

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

SPL UNCLASSIFIED SECTION

Description: Acepromazine maleate, a potent neuroleptic agent with a low order of toxicity, is of particular value in the tranquilization of dogs. Its rapid action and lack of hypnotic effect are added advantages.

Chemistry: 2-acetyl-10-(3-dimethylaminopropyl) phenothiazine hydrogen maleate.

Acepromazine Maleate

image description
image description

DESCRIPTION SECTION

Mode of Action: Acepromazine maleate has a depressant effect on the central nervous system and therefore causes sedation, muscular relaxation and a reduction in spontaneous activity. It acts rapidly, exerting a prompt and pronounced calming effect. It is an effective preanesthetic agent and lowers the dosage requirement of general anesthetics.

VETERINARY INDICATIONS SECTION

Indications: As an aid in tranquilization and as a preanesthetic agent in dogs.

Acepromazine Maleate Tablets can be used as an aid in controlling intractable animals during examination, treatment, grooming, x-ray and minor surgical procedures.

DOSAGE & ADMINISTRATION SECTION

Dosage and Administration: Dogs: 0.25-1.0 mg/lb of body weight. Dosage may be repeated as required.

ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION

Animal Safety: Acute and chronic toxicity studies have shown a very low order of toxicity for acepromazine maleate.

A safety study using elevated dosages of acepromazine maleate demonstrated no adverse reactions even when administered at three times the upper limit of the recommended daily dosage (3.0 mg/lb body weight). The clinical observation for this high dosage was mild depression which disappeared in most dogs 24 hours after termination of dosing.

The only occurrence of adverse reaction during numerous clinical trials was a very mild respiratory distress (reverse sneeze) which was transient in nature and had no effect on the desired action of the drug.

CONTRAINDICATIONS SECTION

Contraindications: Phenothiazines may potentiate the toxicity of organophosphates. Therefore, do not use acepromazine maleate to control tremors associated with organic phosphate poisoning.

Do not use in conjunction with organophosphorus vermifuges or ectoparasiticides, including flea collars.

Do not use with procaine hydrochloride.

WARNINGS SECTION

Warning: Do not use in animals intended for human consumption.

Keep Acepromazine Maleate Tablets in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

PRECAUTIONS SECTION

Precautions: Tranquilizers are potent central nervous system depressants, and they can cause marked sedation with suppression of the sympathetic nervous system. Tranquilizers can produce prolonged depression or motor restlessness when given in excessive amounts or when given to sensitive animals.

Tranquilizers are additive in action to the actions of other depressants and will potentiate general anesthesia. Tranquilizers should be administered in smaller doses and with greater care during general anesthesia and also to animals exhibiting symptoms of stress, debilitation, cardiac disease, sympathetic blockade, hypovolemia or shock. Acepromazine, like other phenothiazine derivatives, is detoxified in the liver; therefore, it should be used with caution on animals with a previous history of liver dysfunction or leukopenia.

Epinephrine is contraindicated for treatment of acute hypotension produced by phenothiazine-derivative tranquilizers since further depression of blood pressure can occur.

Phenothiazines should be used with caution when followed by epidural anesthetic procedures because they may potentiate the arterial hypotensive effects of local anesthetics.

ADVERSE REACTIONS SECTION

Adverse Reactions: A few rare but serious occurrences of idiosyncratic reactions to acepromazine may occur in dogs following oral or parenteral administration. These potentially serious adverse reactions include behavioral disorders in dogs such as aggression, biting/chewing, and nervousness.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact ZyVet Animal Health Inc. at 1-877-779-9838.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae

STORAGE AND HANDLING SECTION

Storage: Store at 20° - 25°C (68° - 77°F). Excursions permitted to 40°C (104°F).

HOW SUPPLIED SECTION

How Supplied: Acepromazine Maleate Tablets are available in light pink to peach colored for 10 mg and light yellow to yellow colored for 25 mg, may be spotted, round, uncoated tablets debossed with "35" and "U" and "37" and "U" respectively on one side and quarter-scored on the other side. Acepromazine Maleate Tablets are supplied in bottles containing 100 and 500 tablets.

NDC 86117-049-07 – 10 mg – 100 tablets

NDC 86117-049-12 – 10 mg – 500 tablets

NDC 86117-050-07 – 25 mg – 100 tablets

NDC 86117-050-12 – 25 mg – 500 tablets

Approved by FDA under ANADA # 200-757

SPL UNCLASSIFIED SECTION

Manufactured by:

Zydus Animal Health and Investments Limited, Ahmedabad, India.

Distributed by:

ZyVet Animal Health Inc

Pennington, NJ 08534

2105363

Rev.: 05/26

Principal Display Panel - Bottle Label, 10 mg – 100 Tablets

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 86117-049-07

Acepromazine

Maleate Tablets

10 mg

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Approved by FDA under ANADA # 200-757

Net Contents:

100 Tablets

10 mg 100 Count
10 mg 100 Count

Principal Display Panel - Bottle Label, 10 mg – 500 Tablets

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 86117-049-12

Acepromazine

Maleate Tablets

10 mg

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Approved by FDA under ANADA # 200-757

Net Contents:

500 Tablets

10 mg 500 Count
10 mg 500 Count

Principal Display Panel - Bottle Label, 25 mg – 100 Tablets

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 86117-050-07

Acepromazine

Maleate Tablets

25 mg

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Net Contents:

100 Tablets

25 mg 100 Count
25 mg 100 Count

Principal Display Panel - Bottle Label, 25 mg – 500 Tablets

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 86117-050-12

Acepromazine

Maleate Tablets

25 mg

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Approved by FDA under ANADA # 200-757

Net Contents:

500 Tablets

25 mg 500 Count
25 mg 500 Count

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
86117-04986117-049-07, 86117-049-12
86117-05086117-050-07, 86117-050-12

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
ACEPROMAZINE MALEATE37862HP2OMACTIB
ACEPROMAZINE MALEATE37862HP2OMACTIB

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
12023-11-10full-release2026-06-01 02:42:34

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.